News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
685,571 Results
Type
Article (39049)
Company Profile (279)
Press Release (646243)
Section
Business (203865)
Career Advice (1991)
Deals (35363)
Drug Delivery (85)
Drug Development (80799)
Employer Resources (168)
FDA (16086)
Job Trends (14805)
News (344543)
Policy (32436)
Tag
Academia (2530)
Alliances (49086)
Alzheimer's disease (1229)
Approvals (16018)
Artificial intelligence (130)
Bankruptcy (352)
Best Places to Work (11534)
Biotechnology (200)
Breast cancer (120)
Cancer (1081)
Cardiovascular disease (97)
Career advice (1660)
Cell therapy (232)
Clinical research (64240)
Collaboration (387)
Compensation (197)
COVID-19 (2530)
C-suite (94)
Data (1119)
Diabetes (152)
Diagnostics (6138)
Earnings (84817)
Employer resources (146)
Events (109472)
Executive appointments (310)
FDA (16621)
Funding (349)
Gene therapy (177)
GLP-1 (575)
Government (4325)
Healthcare (18669)
Infectious disease (2615)
Inflammatory bowel disease (106)
Interviews (308)
IPO (16297)
Job creations (3624)
Job search strategy (1417)
Layoffs (412)
Legal (7853)
Lung cancer (170)
Manufacturing (176)
Medical device (13174)
Medtech (13179)
Mergers & acquisitions (19141)
Metabolic disorders (401)
Neuroscience (1504)
NextGen Class of 2024 (6499)
Non-profit (4464)
Northern California (1476)
Obesity (231)
Opinion (179)
Patents (102)
People (56271)
Phase I (19951)
Phase II (28299)
Phase III (21095)
Pipeline (455)
Postmarket research (2553)
Preclinical (8492)
Radiopharmaceuticals (236)
Rare diseases (218)
Real estate (5890)
Regulatory (21517)
Research institute (2309)
Resumes & cover letters (349)
Southern California (1298)
Startups (3562)
United States (13446)
Vaccines (548)
Weight loss (167)
Date
Today (133)
Last 7 days (787)
Last 30 days (3778)
Last 365 days (35624)
2024 (32677)
2023 (40075)
2022 (51173)
2021 (55712)
2020 (54087)
2019 (46541)
2018 (35019)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (713)
Arizona (192)
Asia (37118)
Australia (6057)
California (3318)
Canada (1289)
China (247)
Colorado (144)
Connecticut (152)
Europe (79501)
Florida (458)
Georgia (116)
Illinois (341)
Indiana (196)
Kansas (96)
Maryland (575)
Massachusetts (2603)
Michigan (157)
Minnesota (272)
New Jersey (952)
New York (957)
North Carolina (701)
Northern California (1476)
Ohio (139)
Pennsylvania (843)
South America (1091)
Southern California (1298)
Texas (461)
Utah (90)
Washington State (360)
685,571 Results for "renovorx inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx’s Pivotal Phase III TIGeR-PaC Clinical Trial
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced today that the University of Nebraska Medical Center (UNMC) is now enrolling patients with Locally Advanced Pancreatic Cancer (LAPC) in the Company’s ongoing pivotal Phase III TIGeR-PaC clinical trial.
June 26, 2024
·
9 min read
Drug Development
Publication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential of RenovoRx’s TAMP™ Therapy Platform to Improve Targeted Cancer Drug Treatment Delivery
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced a publication of pre-clinical studies supporting the efficacy and drug delivery mechanism of RenovoRx’s Trans-Arterial Micro-Perfusion (“TAMP”) therapy platform.
May 21, 2024
·
9 min read
Press Releases
Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx’s Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial
November 20, 2024
·
10 min read
Business
RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships
RenovoRx, Inc. announced that Ryan Witt has joined the Company in the new role as Senior Vice President, Head of Corporate Strategy and Partnerships.
June 10, 2024
·
8 min read
Press Releases
RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights
November 14, 2024
·
13 min read
Biotech Bay
RenovoRx CEO Issues Update Letter to Shareholders - May 30, 2024
RenovoRx, Inc., a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, provided a letter to shareholders from Chief Executive Officer, Shaun Bagai.
May 30, 2024
·
10 min read
Biotech Bay
RenovoRx to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024
RenovoRx, Inc today announced that Shaun Bagai, RenovoRx’s Chief Executive Officer, will present at the Canaccord Genuity 2024 Horizons in Oncology Virtual Conference to be held on April 15, 2024.
April 5, 2024
·
7 min read
Biotech Bay
RenovoRx Announces $11.1 Million at Market Private Placement
RenovoRx, Inc. today announced the execution of definitive subscription agreements with accredited investors for a private placement which is expected to result in gross proceeds of approximately $11.1 million to RenovoRx, before deducting offering expenses.
April 8, 2024
·
9 min read
Biotech Bay
RenovoRx to Present at the 36th Annual ROTH Conference on March 19, 2024
RenovoRx, Inc today announced that Shaun Bagai, RenovoRx’s Chief Executive Officer, will present at the 36th Annual ROTH Conference to be held March 17-19, 2024 in Dana Point, CA.
March 12, 2024
·
7 min read
Biotech Bay
RenovoRx CEO Shaun R. Bagai to Present at the Aegis Capital Virtual Conference on May 9, 2024
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that Shaun R. Bagai, Chief Executive Officer, will present at the Aegis Capital Virtual Conference being held on May 7-9, 2024.
May 2, 2024
·
7 min read
1 of 68,558
Next